ALBUQUERQUE, N.M., Jan. 24 /PRNewswire/ -- Exagen Diagnostics, Inc., which
develops and commercializes genomic marker-based in vitro diagnostic (IVD)
kits for prognosis and prediction of treatment response, today announced that
Robert Mignatti has joined the company as president and COO. He oversees
Exagen's day-to-day operations, as well as company alliances. Exagen CEO Jim
McClintic, who joined the company in October, will continue to guide the
company's strategic direction.
"Our mission is to focus innovative genomic and computational science on
creating leading-edge markers and tests that individualize patient care
worldwide," said McClintic. "Bob's expertise in business development and
planning, strategic partnerships and acquisitions, and developing key
personnel makes him a very strong asset as we build the management team that
will elevate Exagen to its next phase of growth."
Mignatti comes to Exagen with 33 years of laboratory and kit-based
diagnostics experience, including senior management and sales roles at
Esoterix, Inc., Allergy Testing Laboratory, Kallestad Diagnostics, Inc. and
Baxter International. At Esoterix, which provides specialty value-added
laboratory testing information services, Mignatti served as executive vice
president and COO, working directly with McClintic for the past five years.
Last year, McClintic and Mignatti led the sale of Esoterix to LabCorp, Inc.
for $150 million.
"This is an exciting business opportunity because Exagen will be launching
the first IVD kits to detect changes in DNA copy number in tumor tissue to
predict risk of recurrence for both hormone receptor (HR)-positive and
HR-negative breast cancer patients," said Mignatti. "It's also a privilege to
help lead the commercialization of a scientific advancement that has the
potential to significantly improve the quality of life for people with serious
About Exagen Diagnostics, Inc.
As an emerging leader in the development of prognostic and predictive in
vitro diagnostic (IVD) kits, Exagen Diagnostics is uniquely able to discover,
validate and productize small sets of genomic markers for use in oncology,
infectious disease and other indications. Exagen aims to commercialize IVD
kits that can be performed by existing diagnostic laboratories and to develop
tests that accompany the launch of new therapeutics and/or support
pharmaceutical R&D/Phase IV. For more information, visit
SOURCE Exagen Diagnostics, Inc.